PUBLICATIONS

Manuscripts

  1. Hornbacher R*, Gully B*, Brown ZE*, Brown JC, Magill M, Cioe PA, Swift RM, Sanna PP, Haass-Koffler CL. Probenecid as a potential new pharmacotherapy for alcohol use disorder: a randomized placebo-controlled alcohol interaction trial (Alcohol: Clinical and Experimental Research, PMID: 39472130
  2. Gully B*, Brown ZE*, Hornbacher R*, Brown JC, Back, S, McCance-Katz EF, Swift RM, Haass-Koffler CL. Oxytocin reduces noradrenergic-induced opioid-like withdrawal symptoms in individuals on opioid agonist therapy (Biol Psychiatry: Global Open Science, 2024 in press)
  3. Eaton E*, Capone C*, Gully BJ, Brown ZE, Monnig M, Worden M, Swift RM, Haass-Koffler CL. Design and Methodology of the First Open-Label Trial of MDMA-Assisted Therapy for Veterans with PTSD and Alcohol Use Disorders: Considerations for a Randomized Controlled Trial. Contemporary Clinical Trials Communications, 2024 PMID: 39262902
  4. Soliman P*, Curley DE*, Eaton E, Capone C and Haass-Koffler CL. In the New Era of Psychedelic Assisted Therapy A Systematic Review of Study Methodology in Randomized Controlled Trials, 2024 Psychopharmacology. PMID: 38683460
  5. Nelson MJ, Soliman P, Rhew R, Cassidy RN, Haass-Koffler CL. Disruption of Circadian Rhythms Promotes Alcohol Use. Alcohol and Alcoholism 2023 PMID:38123479 preregistered io/azf4m
  6. Gully JB, Eaton E, Capone C and Haass-Koffler CL. Treating Post Traumatic Stress Disorder and Alcohol Use Disorder comorbidity: current pharmacological therapies and Future of MDMA-integrated Psychotherapy. 2023 J Psychopharmacology PMID: 38009477
  7. Soliman P, Amaefuna I, Gully JB and Haass-Koffler CL. Evaluating the Readability of Online Patient Facing Resources for Alcohol Use Disorder. 2023 Alcohol PMID: 37661000
  8. Haass-Koffler CL, Magill M, Cannella N, Brown JC, Aoun EA, Cioe PA, Sinha R, Swift RM, Ciccocioppo R, Leggio L. Mifepristone as a pharmacological intervention for stress-Induced alcohol craving: a human laboratory study. Addiction Biology 2023 PMID: 37369125
  9. Haass-Koffler CL Utilizing precision medicine to treat Alcohol Use Disorder: A commentary on the a1 receptor antagonist. Alcohol: Clinical and Experimental Research 2023 PMID: 36852535
  10. Haass-Koffler CL and Shellfer DJ Neuroscience targets and human studies: future translational efforts in the stress system. Neuropsychopharmacology 2023 PMID: 36725866</
  11. Monnig M, Clark SE, Avila JC, Sokolovsky A, Treloar Padovano H, Goodyear K, Aston ER, Haass-Koffler CL, Tidey J, Ahluwalia JS and Monti PM. COVID-19-Related Stressors and Clinical Mental Health Symptoms in a Northeast US Sample. International Journal of Environmental Research and Public Health, 2023 PMID: 36674123
  12. Haass-Koffler CL, Francis TC, Gandhi P, Patel R, Naemmuddin M, Nilsen CK, Bartlett SE, Bonci A, Vasile S, Hood B, Suyama E, Hedrick MP, Smith LH, Limpert AS, Roberto M, Cosford ND and Sheffler DJ. Development of a High-Throughput Screen to Identify Novel Modulators of the Corticotropin Releasing Factor Binding Protein. 2023 Society for Laboratory Automation and Screening Discovery (SLAS) PMID: 36210051
  13. Curley DE, Vasaturo-Kolodner T, Cannella N, Ciccocioppo R and Haass-Koffler CL. Yohimbine as pharmacological probe for alcohol research: a systematic review in humans and rodents. Neuropsychopharmacology 2022 PMID: 35760866
  14. Lunerti V; Hongwu L; Benvenuti F; Shen Q; Domi A; Soverchia L; Di Martino RMC; Bottegoni G; Haass-Koffler CL, Cannella N. The multitarget FAAH inhibitor/D3 partial agonist ARN15381 decreases nicotine self-administration in male rats. Eur J Pharmacol 2022 PMID: 35690082
  15. Varodayan FP, Patel RR, Matzeu A, Wolfe SA, Curley DE, Khom S, Gandhi P, Rodriguez L, Bajo M, D’Ambrosio S, Sun H, Kerr TM, Gonzales RA, Leggio L, Natividad LA, Haass-Koffler CL, Fardon M, Roberto M. Alcohol Use Disorder compromises the amygdala noradrenergic system 2022 Biol Psychiatry PMID: 35430085
  16. Curley DE, Webb A, Sheffler DJ, Haass-Koffler, CL. Corticotropin releasing factor binding protein as a novel target to restore brain homeostasis: lessons learned from alcohol use disorder research. 2021 Frontiers in Behavioral Neuroscience, Section Motivation and Reward. PMID: 34912198
  17. Haass-Koffler CL, Perciballi R, Magill M, Loche A, Cacciaglia R, Leggio L. and Swift RM An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder 2021 Psychopharmacology PMID: 34731268
  18. Monnig MA, Treloar Padovano H, Sokolovsky A, DeCost G, Aston E, Haass-Koffler CL, Szapary C, Moyo P, Avila J, Tidey J, Monti, PM, and Ahluwalia J. Associations of Substance Use with Behavioral Adherence to CDC Guidelines for COVID-19 Mitigation 2021 Journal of Medical Internet Research PMID: 34591780
  19. Goodyear Chavanne K, Vasaturo-Kolodner T, Kenna GA, Swift RM, Leggio L and Haass-Koffler CL. Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for participants with alcohol use disorder. 2021 The American Journal of Drug and Alcohol Abuse (AJDAA) PMID: 34582281
  20. Zywiak WH, Haass-Koffler CL, Olinsky A, Cavicchio L, Ciliberto DJ. Some Alcohol-Related Consequences for Women May Signal an Escape from Interpersonal Violence. Special issue: Gender and Women’s Studies and Health Care. 2021 Advances in Applied Sociology 2021
  21. Farokhnia M, Abshire KM, Hammer A, Saravakumar A, Cobbina E, You ZB, Haass-Koffler CL, Lee MR, Akhlaghi F, Leggio L. Neuroendocrine response to exogenous ghrelin administration, combined with alcohol, in heavy-drinking individuals: Findings from a randomized, double-blind, placebo-controlled human laboratory study Int J Neuropsychopharmacology 2021 PMID: 33560411 Featured on the NIDA IRP website as the July 2021 ‘Paper of the Month
  22. Brown ZE, Portis SM, Vasaturo-Kolodner T, Fleig C, Swift RM, Haass-Koffler CL. Randomized controlled trials for alcohol use disorder during the COVID-19 pandemic Alcohol 2021 PMID: 33434615
  23. Stopponi S, Fotio Y, Cifani C, Li H, Haass-Koffler CL, Cannella N, Demopulos G, Gaitanaris G, Ciccocioppo R. Andrographis paniculata and its main bioactive ingredient andrographolide decreases alcohol drinking and seeking in rats through activation of nuclear PPARgamma pathway Alcohol and Alcoholism 2021 PMID: 33401299
  24. Portis SM, Haass-Koffler CL. New Microglial Mechanisms Revealed in Alcohol Use Disorder: How Does that Translate? Invited Commentary Biological Psychiatry 2020 PMID: 33213701
  25. Haass-Koffler CL, Piacentino D, Li X, Long VM, Lee M, Kenna GA and Leggio L. Differences in sociodemographic and alcohol-related clinical characteristics between treatment seekers and non-treatment seekers and their role in predicting outcomes in the COMBINE study for alcohol use disorder Alcoholism: Clinical and Experimental Research 2020 PMID: 32997422 Selected Article: ACER Article of Public Interest (API)
  26. Haass-Koffler CL, Perciballi R. Alcohol Tolerance in Human Laboratory Studies for Medications Development to treat Alcohol Use Disorder, Alcohol and Alcoholism 2020 PMID: 31950152; PMC7082491
  27. Haass-Koffler CL, Cannella N and Ciccocioppo R. Translational dynamics of alcohol tolerance between preclinical models and human laboratory studies, Special Issue on: Advancing the Translation between Clinical and Preclinical Models of Individual Differences in Vulnerability to Substance Use Disorders, Experimental and Clinical Psychopharmacology 2020 PMID:32212746
  28. Haass-Koffler CL and Schank JR, Neurobiological Targets in Translational Addiction Research, Editorial for Special Issue: Translational Research in the Neurobiological Mechanisms of Alcohol and Substance Use Disorders, Neurotherapeutics 2020 PMID: 31965552; PMCID7007449
  29. Haass-Koffler CL. Protein Tyrosine Phosphatase β/ζ and alcohol use disorder: A Commentary Alcoholism: Clinical and Experimental Research 2020 PMID: 32343842
  30. Haass-Koffler CL, Perciballi R, Brown Z, Zywiak WH, Lee M, Kurtis J, Swift RM, and Leggio L. Relationship between cotinine levels and peripheral endogenous concentrations of oxytocin, beta-endorphin and orexin in individuals with both alcohol and nicotine use disorders The American Journal on Addictions 2020 PMID: 32488890
  31. Haass-Koffler CL, Souza RS, Wilmott J, Aston ER, Song JH. A combined alcohol and smoking cue-reactivity paradigm in people who drink heavily and smoke cigarettes: preliminary findings Alcohol and Alcoholism 2020 PMID: 32984874
  32. Haass-Koffler CL, Long VM, Farokhnia M, Magill M, Kenna GA, Swift RM and Leggio L. Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: results from a double-blind, placebo-controlled human laboratory study Neuropharmacology  2019 PMID: 31310775; PMC6745267 Selected Article: presented by Dr. George Koob at the 152nd Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism
  33. Tunstall BJ, Lorrai I, McConnell SA, Gazo KL, Zallar LJ, Di Guglielmo G, Haass-Koffler CL, Repunte-Canonigo V, Koob GF, Vendruscolo LF, Sanna Probenecid Reduces Alcohol Drinking in Rats: is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder? Alcohol and Alcoholism 2019 PMID: 31535696; PMC6751410
  34. Goodyear Chavanne K and Haass-Koffler CL Opioid craving in human laboratory settings: a review of the challenges and limitations, Invited Review for Special Issue: Neurobiological Targets in Translational Addiction Research, Neurotherapeutics 2019 PMID: 31650431; PMC7007448
  35. Haass-Koffler CL, Swift RM and Leggio L. Noradrenergic targets in Alcohol Use Disorder, invited to contribute Special Issue focuses on Promising Alcohol Addiction Targets Psychopharmacology, 2018. PMID:29460163: PMC5995154
  36. Haass-Koffler CL. Role of Corticotropin Releasing Factor Binding Protein in the stress system: a strange case of Dr. Jekyll and Mr. Hyde? Invited Review as Young Investigator Awardee, Volterra Conference, Alcohol, 2018 PMID: 29510883; PMC5899053
  37. Aoun EG, Jimanez V, Vendruscolo LF, Walter NAR, Barbier E, Ferulli A, Haass-Koffler CL, Darakjian P, Lee, MR, Addolorato G, Heilig M, Hitzemann R, Koob GF, Grant KA, and Leggio L. Relationship between the aldosterone – mineralocorticoid receptor pathway and alcohol drinking: preliminary translational findings across rats, monkeys and humans Molecular Psychiatry  2019 PMID: 28461696 PMCID: PMC5668213 Selected Article: featured on the NIAAA press release and selected as an NIH-wide press and Selected Article: NIDA paper of the month
  38. Haass-Koffler CL, Goodyear K, Zywiak W, Kenna GA, Leggio L and Swift RM, Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. Alcohol and Alcoholism, 2018 PMID: 29281033; PMID: PMC5913672
  39. Haass-Koffler CL, Goodyear K, Zywiak W, Kenna GA, Leggio L and Swift RM, Corrigendum: Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. Alcohol and Alcoholism, 2018 PMID: 29718153; PMID: PMC5913672
  40. Haass-Koffler CL, Goodyear K, Loche A, Long VM, Cacciaglia R, Swift RM, and Leggio L. Administration of the Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulator GET 73 With Alcohol: A Translational Study in Rats and Humans Journal Psychopharmacology 2018 PMID: 29361897; PMC701457
  41. Goodyear, K, Haass-Koffler CL, Chavanne D, Opioid use and stigma: what really matters?” Drug and Alcohol Dependence 2018 PMID: 29499554; PMC6097242
  42. Haass-Koffler CL, Goodyear K, Zywiak WH, Magill M, Wallace PM, Eltinge S, Long VM, Jayaram-Lindström N, Swift RM, Kenna GA, Leggio. Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin Drug Alcohol Depend 2017 PMID: 28551590. PMCID: PMC5534374 Selected Article in the New England Journal Medicine (NEJM) Journal Watch
  43. Haass-Koffler CL, Goodyear K, Long VM, Loche A, Cacciaglia R, Swift RM, and Leggio L. Phase I randomized clinical trial for the safety, tolerability and pharmacokinetics of the mGluR5 negative allosteric modulator GET73 following single and repeated doses in healthy volunteers, Eur J Pharm Sci 2017 PMID: 28778464, PMC5776031
  44. Haass-Koffler CL, Goodyear K, Long VM, Tran HH, Loche A, Cacciaglia R, Swift RM, Leggio L, Dataset for Phase I clinical trial for safety and tolerability of GET 73 in single and repeated doses including preliminary pharmacokinetics parameters. Data in Brief, 2017 PMID: 29214202, PMCID: PMC5712048
  45. Haass-Koffler CL,Akhlaghi, F, Swift RM, Leggio L. Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks? Journal of Psychopharmacology 2017 PMID: 28093021;  PMC5768306
  46. Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM and Leggio L. Role of the alpha-1 Blocker Doxazosin in Alcohol Dependence: a Proof-of-Concept Randomized Double-Blind Placebo-Controlled Trial. Addiction Biology 2016 PMID: 26037245; PMCID: PMC4668239
  47. Haass-Koffler CL, Giovenco DE, Lee MR, Zywiak WH, de la Monte SM, Kenna GA, Swift RM and Leggio L. Serum insulin levels are reduced by intravenous ghrelin administration but do not correlate with alcohol craving in alcohol dependent individuals, International Journal of Neuropsychopharmacology, 2016. PMID: 27207912; PMCID: PMC5091823
  48. Haass-Koffler CL, Henry AT, Melkus G, Simms JA, Naemmuddin M, Nilsen CK, Schwandt ML, Hodgkinson CA, Magill M, Lasek AW, Momenam R, Bartlett SE, Swift RM, Bonci A, and Leggio L. Defining the role of Corticotropin Releasing Factor Binding Protein in alcohol consumption, Translational Psychiatry  2016 PMID: 27845775, PMCID: PMC3434418 Recipient: New Investigator Award Volterra, Italy
  49. Haass-Koffler CL, Leggio L, Davidson D and Swift RM. The Effect of Idazoxan on Human Alcohol Intoxication and Alcohol Pharmacokinetics. Alcoholism: Clinical and Experimental Research 2015 PMID: 25833022; PMCID: PMC4384190
  50. Haass-Koffler CL, Aoun EG, Kenna GA, de la Monte SM, Swift RM and Leggio L. Exogenous intravenous ghrelin administration decreases Leptin serum level and increases alcohol craving. Transitional Psychiatry, 2015. PMID: 26418274; PMC5545639. Selected Article: featured on the NIDA Science Highlights
  51. Aoun EG, Lee MR, Haass-Koffler CL, Swift MR, Addolorato G, Kenna GA and Leggio L, Relationship between the thyroid axis and alcohol craving. Alcohol and Alcoholism 2015 PMID: 25433251; PMC4266183
  52. Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Vuittonet C, Fricchione S, Brickley M, Beaucage K, Haass-Koffler CL and Leggio L. Ondansetron reduces naturalistic drinking in non-treatment seeking alcohol dependent subjects with LL 5’-HTTLPR alleles: a laboratory study. Alcoholism: Clinical and Experimental Research 2014 PMID: 24773166; PMCID: PMC4047179
  53. Haass-Koffler CL Leggio L, and Kenna GA. Pharmacological Approaches to Reducing Craving in Alcohol Use Disorders, CNS Drugs 2014 PMID: 24573997; PMCID: PMC3990000
  54. Vuittonet CL, Halse M, Leggio L, Fricchione S, Brickley M, Haass-Koffler CL, Tavares T, Swift RM and Kenna, GA. Pharmacotherapy for Alcoholic Patients with Alcoholic Liver Disease. American Journal of Health-System Pharmacy 2014 PMID: 25027533; PMCID: PMC4170837
  55. Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Fricchione S, Brickley M, Beaucage K, Haass-Koffler CL and Leggio L. Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: Exploratory findings. Alcohol 2014 PMID: 25212749; PMCID: PMC4163011
  56. Chatterjee S, Santos N, Holgate J, Haass-Koffler CL, Hopf W, Kharazia V, Lester L, Bonci A and Bartlett SE. The α5 Subunit Regulates the Expression and Function of α4*-Containing Neuronal Nicotinic Acetylcholine Receptors in the Ventral-Tegmental Area. PLoS One 2013 PMID: 23869214; PMCID: PMC3712017
  57. Haass-Koffler CL and Kenna GA. Bacchus by Caravaggio as the visual diagnosis of Alcohol Use Disorder (AUD) from the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), Frontiers in Psychiatry 2013 PMID: 23964247; PMCID: PMC3737464. Recipient: best performing articles in Frontiers
  58. Haass-Koffler CL, Naeemuddin M and Bartlett SE. An Analytical Tool that Quantifies Cellular Morphology changes from Three Dimensional Fluorescence Images. Journal of Visualized Experiments 2012 PMID: 229551512; PMCID: PMC3486772 VIDEO
  59. Haass-Koffler CL and Bartlett SE. Stress and Addiction: Contribution of Corticotropin Releasing Factor System in Neuroplasticity, Special Topic Frontiers, Frontiers In Molecular Neuroscience 2012 PMID: 22973190; PMCID; PMC3434418
  60. Simms JA, Haass-Koffler CL, Bito-Onon J and Bartlett SE. Mifepristone in the Central Nucleus of the Amygdala Reduces Yohimbine Stress-Induced Reinstatement of Ethanol seeking. Neuropsycopharmacology 2012 PMID: 22048462; PMCID: PMC3280651

 

Book Chapters

  • McCance-Katz EF and Haass-Koffler CL. Principles of Addiction Medicine, 7th Edition, Chapter 10: The Pharmacology of nonalcoholic Sedative Hypnotics, American Society Addiction Medicine (ASAM) edited by Miller S, Rosenthal R, Saitz R, Tetrult J, Levy S and Saxon A, 2023
  • Haass-Koffler CL and McCance-Katz EF. Essentials of Addiction Medicine, 6th Edition, Chapter 8: The Pharmacology of Nonalcoholic Sedative Hypnotics, American Society Addiction Medicine (ASAM) edited by Miller S, Rosenthal R, Fiellin D, and Saitz R, 2019
  • Haass-Koffler CL and McCance-Katz EF. Principles of Addiction Medicine, 6th Edition, Chapter 8: The Pharmacology of nonalcoholic Sedative Hypnotics, American Society Addiction Medicine (ASAM) edited by Miller S, Rosenthal R, Fiellin D, and Saitz R, 2018
  • Haass-Koffler CL and McCance-Katz EF. Lowinson & Ruiz’s (Eds), Substance Abuse: A Comprehensive Textbook, Fifth Edition, Section 7: Management of Associated Medical Conditions, 53: Medication Interactions. Lippincott Wilkins, 2011; JAMA 307(17):1868-1869. doi:10.1001/jama.307.17.1868 2012

 

Clinical Publications

  • Perciballi R and Haass-Koffler CL. Il target noradrinergico per lo sviluppo delle farmacoterapie per l’alcolismo, Medicina delle Dipendenze Alcol: Nuove e vecchie frontiere (invited review), MDD 42, 2021
  • Haass-Koffler CL, Perciballii R, Brown ZE, Swift RM and Leggio L. When clinical practice precedes clinical research: A case study of personalized addiction medicine Editorial, Rivista di Alcologia: 41, 1, 2020, Firenze: Centro Alcologico Regionale Toscano, 2020
  • Haass-Koffler CL and Leggio L. Doxazosin: a new treatment for alcohol use disorder. Editorial, Rivista di Alcologia: 31, 1, 2017, Firenze: Centro Alcologico Regionale Toscano, 2017
  • Haass-Koffler CL and Gasper JJ. Guidelines for physicians in psychiatric hospitals: Effectiveness, toxicity and drug interactions of psychotropic medications, Department Public Health, Community Behavioral Health Services, San Francisco General Hospital (SFGH) 2009
  • Haass-Koffler CL. Formulary review: Angiotensin II Type 1 Receptor Antagonist, Pharmacy & Therapeutics Committee, Department of Public Health, Laguna Honda Hospital 2008
  • Haass-Koffler CL and Gasper JJ. Case Report:  Pharmacokinetics of buprenorphine SL by alternative routes, Department Public Health, Community Behavioral Health Services, San Francisco General Hospital (SFGH) 2008
  • Haass-Koffler CL and Gasper JJ. Benzodiazepine withdrawal, Department Public Health, Community Behavioral Health Services, San Francisco General Hospital (SFGH) 2008
  • Haass-Koffler CL and Gasper JJ. Fentanyl TD tolerance, Department Public Health, Community Behavioral Health Services, San Francisco General Hospital (SFGH) 2008
  • Haass-Koffler CL and Gasper JJ. Drug-drug interaction between antiretroviral therapy and psychoactive drugs, Department Public Health, Community Behavioral Health Services, San Francisco General Hospital (SFGH) 2008
  • Haass-Koffler CL and Gasper JJ. Case report: Schizophrenia & varenicline (Chantix), Department Public Health, Community Behavioral Health Services, San Francisco General Hospital (SFGH) 2008
  • Haass-Koffler CL and Gasper JJ. Stress and activation of k-opioid, Department Public Health, Community Behavioral Health Services, San Francisco General Hospital (SFGH) 2008
  • Haass-Koffler CL and Gasper JJ. Metabolic syndrome in patients treated with the second-generation antipsychotic, Department Public Health, Community Behavioral Health Services, San Francisco General Hospital (SFGH) 2007